Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01889160 | Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels | PHASE1 | COMPLETED | 44 | — | — | Jul 1, 2013 | Dec 1, 2013 | Jun 25, 2015 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part A Active | EXPERIMENTAL | AZD4721 Solution |
| Part A Placebo | PLACEBO_COMPARATOR | Placebo for AZD4721 |
| Part B solution | EXPERIMENTAL | AZD4721 Solution |
| Part B Suspension | ACTIVE_COMPARATOR | AZD4721 Suspension |
| Name | Type | Description |
|---|---|---|
| AZD4721 Solution | DRUG | 1-9 mg/mL liquid solution |
| AZD4721 Placebo | DRUG | Liquid solution |
| AZD4721 Suspension | DRUG | 9 mg/g liquid suspension |
Inclusion Criteria: 1. Healthy male and/or female Caucasian (neither Black/African American nor Japanese) volunteers aged 18-50 years. ("Healthy" is as determined by medical history and physical examination, clinical laboratory parameters, and ECG ) 2. Females must have a negative pregnancy test at...